Next-Generation Sequencing Reveals High Uncommon EGFR Mutations and Tumour Mutation Burden in a Subgroup of Lung Cancer Patients
暂无分享,去创建一个
Jun Liu | Heng Li | T. Shou | Q. Guo | Xiumei Yang | Gaofeng Li | Yunfei Shi | Yinqiang Liu | G. Guo
[1] Liming Li,et al. Establishment of reference intervals of ten commonly used clinical chemistry analytes: a real-world study in China. , 2021, Biomarkers in Medicine.
[2] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[3] J. Ahn,et al. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Y. Liao,et al. The characteristics of lung cancer in Xuanwei County: A review of differentially expressed genes and noncoding RNAs on cell proliferation and migration. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[5] J. Desai,et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.
[6] Yuwei Cheng,et al. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies. , 2019, The oncologist.
[7] Xin Wang,et al. The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer , 2019, Cancer science.
[8] Yu-An Dong,et al. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. , 2019, The oncologist.
[9] Haifeng Song,et al. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients , 2019, Journal of Hematology & Oncology.
[10] Wanqing Chen,et al. Epidemiology of lung cancer in China , 2018, Thoracic cancer.
[11] B. Guleng,et al. Germline and somatic variations influence the somatic mutational signatures of esophageal squamous cell carcinomas in a Chinese population , 2018, BMC genomics.
[12] J. Szustakowski,et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.
[13] J. Shih,et al. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer , 2018, Molecular Cancer.
[14] A. Fernández-Villar,et al. Environmental tobacco smoke exposure and EGFR and ALK alterations in never smokers' lung cancer. Results from the LCRINS study. , 2017, Cancer letters.
[15] Wei-Chih Liao,et al. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations. , 2017, Lung cancer.
[16] M. Tsao,et al. Uncommon EGFR mutations in advanced non-small cell lung cancer. , 2017, Lung cancer.
[17] M. Socinski,et al. First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[18] B. Han,et al. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. , 2016, Lung cancer.
[19] Chandra Sekhar Pedamallu,et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas , 2016, Nature Genetics.
[20] Lijuan Ye,et al. Distinct epithelial growth factor receptor mutation profile in non-small-cell lung cancer patients from the Xuanwei area of China , 2016, Molecular and clinical oncology.
[21] B. Taylor,et al. deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution , 2016, Genome Biology.
[22] X. Zou,et al. The mortality patterns of lung cancer between 1990 and 2013 in Xuanwei, China. , 2015, Lung cancer.
[23] N. Girard,et al. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[24] L. Sequist,et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.
[25] Yize Xiao,et al. The epidemic status and risk factors of lung cancer in Xuanwei City, Yunnan Province, China , 2012, Frontiers of Medicine.
[26] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[27] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[28] Ping Yang,et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.
[29] M. Ostland,et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Ying Cheng,et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. , 2018, The Lancet. Oncology.
[31] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.